Referanslar

• Koshy M, Villano JL, Dolecek TA, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based reg-istries. JNeurooncol. 2012;107:207-212. google scholar
• Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors di-agnosed in the United States in 2006-2010. Neuro-Oncology. 2013;15-ii56. google scholar
• Batash R, Asna N, Schaffer P, et al. Glioblastoma multiforme, di-agnosis and treatment; Recent literature review. Curr Med Chem. 2017;24:3002-3009. google scholar
• Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: A “state of the science” review. Neuro Oncol. 2014;16:896-913. google scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous sys-tem: A summary. Acta Neuropathol. 2016;131:803-820. google scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773. google scholar
• Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19:764-772. google scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(1):97-109. google scholar
• Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009; 118(1):599-601. google scholar
• Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 3: Recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol. 2018;136(5):805-810. google scholar
• Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469-474. google scholar
• Ferrer VP, Moura Neto V, Mentlein R. Glioma infiltration and extracellular matrix: Key players and modulators. Glia. 2018;66:1542-1565. google scholar
• Chen JT, Mao SF, Li HF, et al. The pathological structure of the perivascular niche in different microvascular patterns of glioblastoma. PLoS One. 2017;12(8):12. doi: 10.1371/jour-nal.pone.018283. google scholar
• Zhao X, Chen RJ, Liu M, Feng JF, Chen J, Hu KL. Remodeling the blood-brain barrier microenvironment by natural products for brain tumor therapy. Acta Pharm Sin B. 2017;7(5):541-553. google scholar
• Nakod PS, Kim Y, Rao SS. Biomimetic models to exam-ine microenvironmental regulation of glioblastoma stem cells. Cancer Lett. 2018;429:41-53. google scholar
• Dey M, Ulasov IV, Lesniak MS. Virotherapy against malignant glioma stem cells. Cancer Lett. 2010;289(1):1-10. google scholar
• Simon T, Gagliano T, Giamas G. Direct effects of anti-angiogenic therapies on tumor cells: VEGF signaling. Trends Mol Med. 2017;23(3):282-292. google scholar
• Fessler E, Borovski T, Medema JP. Endothelial cells induce cancer stem cell features in differentiated glioblastoma cells via bFGF. Mol Cancer. 2015;14:157. google scholar
• Hu F, Ku MC, Markovic D, et al. Glioma associated microglial MMP9 expression is upregulated by TLR2 signalling and sensi-tive to minocycline. Int J Cancer. 2014;135(11):2569-2578. google scholar
• Jakel S, Dimou L. Glial cells and their function in the adult brain: A journey through the history of their ablation. Front Cell Neurosci. 2017;11. doi: 10.3339/fncel.2017.00024 google scholar
• Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31(3):326-341. google scholar
• Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(1):157-173. google scholar
• Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110. google scholar
• Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(1):425-437. google scholar
• Parsons DW, Jones S, Zhang X, et al. An integrated ge-nomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-1812. google scholar
• Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is suffi-cient to establish the glioma hypermethylator phenotype. Nature. 2012;483(1):479-483. google scholar
• Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(1):510-522. google scholar
• Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol. 2013;125(5):621-636. google scholar
• Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20(1):245-254. google scholar
• DeWitt JC, Jordan JT, Frosch MP, et al. Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classifica-tion of tumors of the central nervous system recommendations. Neuro Oncol. 2017;19(12):1640-1650. google scholar
• Labussiere M, Di Stefano AL, Gleize V, et al. TERT promoter mutations in gliomas, genetic associations and clinicopathological correlations. BrJ Cancer. 2014;111(1):2024-2032. google scholar
• Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482:226-231. google scholar
• Chaurasia A, Park SH, Seo JW, et al. Immunohistochemical analy-sis of ATRX, IDH1 and p53 in glioblastoma and their correlations with patient survival. J Korean Med Sci. 2016;31:1208-1214. google scholar
• Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 2013;110(1):6021-6026. google scholar
• Vinagre J, Pinto V, Celestino R, et al. Telomerase promoter mu-tations in cancer: An emerging molecular biomarker? Virchows Arch. 2014;465:119-133. google scholar
• Nakahara Y, Okamoto H, Mineta T, et al. Expression of the Wilms’ tumor gene product WT1 in glioblastomas and medulloblastomas. Brain Tumor Pathol. 2004;21:113-116. google scholar
• Fredriksson NJ, Ny L, Nilsson JA, et al. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nat Genet. 2014;46:1258-1263. google scholar
• Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372:2499-2508. google scholar
• Spiegl-Kreinecker S, Lötsch D, Ghanim B, et al. Prognostic qual-ity of activating TERT promoter mutations in glioblastoma: In-teraction with the rs2853669 polymorphism and patient age at diagnosis. Neuro-Oncology. 2015;17:1231-1240. google scholar
• Olympios N, Gilard V, Marguet F, et al. TERT promoter alterations in glioblastoma: A systematic review. Cancers. 2021;13:1147. google scholar
• Wang TJ, Huang MS, Hong CY, et al. Comparisons of tumor suppressor p53, p21, and p16 gene therapy effects on glioblas-toma tumorigenicity in situ. Biochem Biophys Res Commun. 2001;287:173-180. google scholar
• Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010;2(2):a001107. doi: 10.1101/csh-perspect.a001107 google scholar
• Adorno M, Cordenonsi M, Montagner M, et al. A Mutant-p53/Smad Complex Opposes p63 to Empower TGF^-Induced Metastasis. Cell. 2009;137:87-98. google scholar
• Behling F, Barrantes-Freer A, Skardelly M, et al. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn Pathol. 2016;11:55. doi: 10.1186/s13000-016-0506-2. google scholar
• Bautista F, Paci A, Minard-Colin V, et al. Vemurafenib in pediatric patients with BRAFV 600E mutated high-grade gliomas. Pediatr Blood Cancer. 2014;61(1):1101-1103. google scholar
• Patel R, Leung HY. Targeting the EGFR-family for therapy: Biological challenges and clinical perspective. Curr Pharm Des. 2012;18:2672-2679. google scholar
• Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA. 1992;89(1):4309-4313. google scholar
• Cowppli-Bony A, Bouvier G, Rue M, et al. Brain tumors and hor-monal factors: Review of the epidemiological literature. Cancer Causes Control. 2011;22:697-714. google scholar
• Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246-1256. google scholar
• Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vac-cine in glioblastoma multiforme patients. Expert Opin Biol Ther. 2009;9:1087-1098. google scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. google scholar
• Malmström A, Gr0nberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated ra-diotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(1):916-926. google scholar
• Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblas-toma. Lancet Oncol. 2014;15(9):e395-403. doi: 10.1016/S1470-2045(14)70011-7 google scholar
• Hopkins BD, Hodakoski C, Barrows D, Mense SM, Parsons RE. PTEN function: The long and the short of it. Trends Biochem Sci. 2014;39:183-190. google scholar
• Koul D. PTEN signaling pathways in glioblastoma. Cancer Biol Ther. 2008;7:1321-1325. google scholar
• Knobbe CB, Merlo A, Reifenberger G. PTEN signalling in gliomas. Neuro-Oncology. 2002;4:196-210. google scholar
• La Fougere C, Suchorska B, Bartenstein P, et al. Molecular imag-ing of gliomas with PET: Opportunities and limitations. Neuro Oncol. 2011;13(1):806-819. google scholar
• Kono K, Inoue Y, Nakayama K, et al. The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol. 2001;22(1):1081-1088. google scholar
• Law M, Yang S, Wang H, et al. Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24(1):1989-1998. google scholar
• Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multi-forme: A prospective randomized clinical trial. J Clin Oncol. 2004;22(1):1583-1588. google scholar
• Taphoorn MJ, Stupp R, Coens C, et al. Health-related quality of life in patients with glioblastoma: A randomised controlled trial. Lancet Oncol. 2005;6(1):937-944. google scholar
• Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(1):1527-1535. google scholar
• Wick W, Menn O, Meisner C, et al. Pharmacotherapy of epileptic seizures in glioma patients: Who, when, why and how long? Onkologie. 2005;28(1):391-396. google scholar
• Chaichana KL, Parker SL, Olivi A, et al. Long-term seizure out-comes in adult patients undergoing primary resection of malignant brain astrocytomas. J Neurosurg. 2009;111(1):282-292. google scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(1):987-996. google scholar
• Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolo-mide for newly diagnosed glioblastoma: A randomized phase III clinical trial. J Clin Oncol. 2013;31(1):4085-4091. google scholar
• Murphy ES, Xie H, Merchant TE, Yu JS, Chao ST, Suh JH. Re-view of cranial radiotherapy-induced vasculopathy. J Neurooncol. 2015;122(3):421-429. google scholar
• Heffron TP. Challenges of developing small-molecule kinase in-hibitors for brain tumors and the need for emphasis on free drug levels. Neuro Oncol. 2018;20(3):307-312. google scholar
• Idbaih A, Canney M, Belin L, et al. Safety and feasibility of repeated and transient blood-brain barrier disruption by pulsed ultrasound in patients with recurrent glioblastoma. Clin Cancer Res. 2019;25(13):3793-3801. google scholar
• Brennan CW, Verhaak RG, McKenna A, et al. TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477. google scholar
• Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogene-ity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA. 2013;110(10):4009-4014. google scholar
• Francis JM, Zhang CZ, Maire CL, et al. EGFR variant heterogene-ity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014;4(8):956-971. google scholar
• Neftel C, Laffy J, Filbin MG, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019;178(4):835-849. google scholar
• Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396-1401. google scholar
• Lan X, Jörg DJ, Cavalli FMG, et al. Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature. 2017;549(7671):227-232. google scholar
• Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488(7412):522-526. google scholar
• Ohgaki H, Kim YH, Steinbach JP. Nervous system tumors as-sociated with familial tumor syndromes. Curr Opin Neurol. 2010;23(1):583-591. google scholar
• Jonsson P, Lin AL, Young RJ, et al. Genomic correlates of disease progression and treatment response in prospectively characterized gliomas. Clin Cancer Res. 2019;25(18):5537-5547. google scholar
• Melin BS, Barnholtz-Sloan JS, Wrensch MR, et al. GliomaS-can Consortium. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibil-ity to glioblastoma and non-glioblastoma tumors. Nat Genet. 2017;49(5):789-794. google scholar
• Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006;98(1):1528-1537. google scholar
• Minniti G, Traish D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: Update after an additional 10 years. J Clin Endocrinol Metab. 2005;90(1):800-804. google scholar
• Brada M, Ford D, Ashley S, et al. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. Br Med J. 1992;304(1):1343-1346. google scholar
• Interphone Study Group. Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. Int J Epidemiol. 2010;39(1):675-694. google scholar
• Dziurzynski K, Chang SM, Heimberger AB, et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012;14(1):246-255. google scholar
• Wick W, Platten M. CMV infection and glioma, a highly con-troversial concept struggling in the clinical arena. Neuro Oncol. 2014;16(1):332-333. google scholar
• Connelly JM, Malkin MG. Environmental risk factors for brain tumors. Curr Neurol Neurosci Rep. 2007;7(1):208-214. google scholar
• Bondy ML, Scheurer ME, Malmer B, et al. Brain tumor epidemi-ology: Consensus from the Brain Tumor Epidemiology Consor-tium. Cancer. 2008;113(1):1953-1968. google scholar
• Ostrom QT, Barnholtz-Sloan JS. Current state of our knowledge on brain tumor epidemiology. Curr Neurol Neurosci Rep. 2011;11(1):329-335. google scholar
• Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res. 2004;64:6892-6899. google scholar
• Fukushima T, Favereaux A, Huang H, et al. Genetic alterations in primary glioblastomas in Japan. J Neuropathol Exp Neurol. 2006;65:12-18. google scholar
• UC Clinical Trials.http://www.ucclinicaltrials.com. Accessed on July 10, 2024. google scholar
• Mayo Clinic. http://www.mayoclinic.org. Accessed on July 10, 2024. google scholar
• Clinical Trials at UCSF. http://www.ucsfclinicaltrials.org. Ac-cessed on July 10, 2024. google scholar
• Memorial Sloan Kettering Cancer Centre. http://www.mskcc.org. Accessed on July 10, 2024. google scholar
• Wilson CB. Current concepts in cancer: Brain tumors. N Engl J Med. 1979;300:1469-1471. google scholar
• Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma - Are we there yet? Neuro Oncol. 2013;15(1):4-27. google scholar
• Gramatzki D, Dehler S, Rushing EJ, et al. Glioblastoma in the canton of Zurich, Switzerland revisited, 2005 to 2009. Cancer. 2016;122(16):2206-2215. google scholar
• Jackson CM, Kochel CM, Nirschl CJ, et al. Systemic tolerance mediated by melanoma brain tumors is reversible by radiotherapy and vaccination. Clin Cancer Res. 2016;22(5):1161-1172. google scholar
• Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275-287. google scholar
• Aurelian L. Oncolytic viruses as immunotherapy, progress and remaining challenges. OncoTargets Ther. 2016;9:2627-2637. google scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480-489. google scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint block-ade: A common denominator approach to cancer therapy. Cancer Cell. 2015;27:450-461. google scholar
• Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561-2569. google scholar
• O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with re-current glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984 doi: 10.1126/scitranslmed.aaa0984 google scholar
• Bagley SJ, Desai AS, Linette GP, June CH, O’Rourke DM. CAR T-cell therapy for glioblastoma: Recent clinical advances and future challenges. Neuro Oncol. 2018;20(11):1429-1438. google scholar
• Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. Nature. 2017;545:423-431. google scholar
• Beyar-Katz O, Gill S. Advances in chimeric antigen receptor T cells. Curr Opin Hematol. 2020;27:368-377. google scholar
• Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel im-munotherapies in lymphoid malignancies. Nat Rev Clin Onco. 2016;13:25-40. google scholar
• Brown MP, Ebert LM, Gargett T. Clinical chimeric antigen receptor-T cell therapy: A new and promising treatment modal-ity for glioblastoma. Clin Transl Immunol. 2019;8(5):e1050. doi: 10.1002/cti2.1050 google scholar
• Brown CE, Badie B, Barish ME, et al. Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21:4062-4072. google scholar
• Ahmed N, Brawley V, Hegde M, et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: A phase 1 dose-escalation trial. JAMA Oncol. 2017;3:1094-1101. google scholar
• Kaufmann JK, Chiocca EA. Glioma virus therapies between bench and bedside. Neuro Oncol. 2014;16(3):334-351. google scholar
• Blitz SE, Kappel AD, Gessler FA, et al. Tumor-associated macrophages/microglia in glioblastoma oncolytic virotherapy: A double-edged sword. Int J Mol Sci. 2022;23(3):1808. doi: 10.3390/ijms23031808 google scholar
• Zhou C, Chen Q, Chen Y, Qin CF. Oncolytic Zika virus: New option for glioblastoma treatment. DNA Cell Biol. 2023;42:267-273. google scholar
• Chen Q, Wu J, Ye Q, Ma F, Zhu Q, Wu Y, et al. Treatment of human glioblastoma with a live attenuated Zika virus vaccine can-didate. mBio. 2018;9(5):e01683-18. doi: 10.1128/mBio.01683-18 google scholar
• Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther. 2004;10:958-966. google scholar
• Markert JM, Razdan SN, Kuo HC, et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014;22:1048-1055. google scholar
• Marelli G, Howells A, Lemoine NR, Wang Y. On-colytic viral therapy and the immune system: A double-edged sword against cancer. Front Immunol. 2018;9:866. doi: 10.3389/fimmu.2018.00866 google scholar
• Kicielinski KP, Chiocca EA, Yu JS, et al. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther. 2014;22:1056-1062. google scholar
• Gujar S, Bell J, Diallo JS. SnapShot: Cancer immunother-apy with oncolytic viruses. Cell. 2019;176:1240-1240.e1. doi: 10.1016/j.cell.2019.01.051 google scholar
• Angom RS, Nakka NMR, Bhattacharya S. Advances in glioblas-toma therapy: An update on current approaches. Brain Sci. 2023;13:1536. doi: 10.3390/brainsci13111536 google scholar
• Asija S, Chatterjee A, Yadav S, et al. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. Int Rev Immunol. 2022;41:582-605. google scholar
• Huang B, Li X, Li Y, Zhang J, Zong Z, Zhang H. Current immunotherapies for glioblastoma multiforme. Front Immunol. 2021;11:603911. doi: 10.3389/fimmu.2020.603911 google scholar
• Shoaf ML, Desjardins A. Oncolytic viral therapy for ma-lignant glioma and their application in clinical practice. Neurotherapeutics. 2022;19:1818-1831. google scholar
• Qi Z, Long X, Liu J, Cheng P. Glioblastoma microen-vironment and its reprogramming by oncolytic virother-apy. Front Cell Neurosci. 2022;16:819363. doi: 10.3389/fn-cel.2022.819363. google scholar
• Kamynina M, Tskhovrebova S, Fares J, et al. Oncolytic virus-induced autophagy in glioblastoma. Cancers. 2021;13:3482. doi: 10.3390/cancers13143482 google scholar
• Haddad AF, Young JS, Mummaneni NV, Kasahara N, Aghi MK. Immunologic aspects of viral therapy for glioblastoma and impli-cations for interactions with immunotherapies. J Neuro-Oncol. 2021;152:1-13. google scholar
• Ali S, Xia Q, Muhammad T, et al. Glioblastoma therapy: Ratio-nale for a mesenchymal stem cell-based vehicle to carry recom-binant viruses. Stem Cell Rev Rep. 2022;18:523-543. google scholar
• Desjardins A, Gromeier M, Herndon JE 2nd, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379:150-161. google scholar
• Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. Intergeneric poliovirus recombinants for the treatment of ma-lignant glioma. Proc Natl Acad Sci USA. 2000;97:6803-6808., google scholar
• Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699-708. google scholar
• Hegi ME, Rajakannu P, Weller M. Epidermal growth factor re-ceptor: A re-emerging target in glioblastoma. Curr Opin Neurol. 2012;25:774-779. google scholar
• Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mu-tant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340:626-630. google scholar
• Cancer Genome Atlas Research. Comprehensive genomic char-acterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061-1068. google scholar
• Lee EQ, Kuhn J, Lamborn KR, et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 0502. Neuro Oncol. 2012;14:1511-1518. google scholar
• Wen PY, Chang SM, Lamborn KR, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014;16:567-578. google scholar
• Chinot OL, Wick W, Mason M, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709-722. google scholar
• Sandmann T, Bourgon R, Garcia J, et al. Patients with proneural glioblastoma may derive overall survival benefit from the ad-dition of bevacizumab to first-line radiotherapy and temozolo-mide: retrospective analysis of the AVAglio trial. J Clin Oncol. 2015;33:2735-2744. google scholar
• Pilie PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81-104. google scholar
• Gupta SK, Mladek AC, Carlson BL, et al. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multi-forme xenografts. Clin Cancer Res. 2014;20(14):3730-3741. google scholar
• Venneti S, Thompson CB. Metabolic reprogramming in brain tumors. Annu Rev Pathol. 2017;12:515-545. google scholar
• Agnihotri S, Golbourn B, Huang X, et al. PINK1 is a nega-tive regulator of growth and the Warburg effect in glioblastoma. Cancer Res. 2016;76(16):4708-4719. google scholar
• Agnihotri S, Mansouri S, Burrell K, et al. Ketoconazole and posaconazole selectively target HK2-expressing glioblastoma cells. Clin Cancer Res. 2019;25(2):844-855. google scholar
• Villa GR, Hulce JJ, Zanca C, et al. An LXR-cholesterol axis creates a metabolic co-dependency for brain cancers. Cancer Cell. 2016;30(5):683-693. google scholar
• Rominiyi O, Vanderlinden A, Clenton SJ, et al. Tumour treat-ing fields therapy for glioblastoma: current advances and future directions. BrJ Cancer. 2021; 124:697-709. google scholar
• Olatunji G, Aderinto N, Adefusi T, et al. Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narra-tive review of current evidence. Medicine (Baltimore). 2023 102(48):e36421. doi: 10.1097/MD.0000000000036421 google scholar

Atıflar